...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** BETonMACE Trial is Fully Enrolled and Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: Low Impact Journals

Thanks. Never thought that IF might not be a big consideration for industry. I am a physician who publishes frequently and IF is a big consideration as to where I sent my research.

New Message
Please login to post a reply